nVision Medical is a clinical stage medical device company dedicated to filling the void in female health-related innovation. In November 2015 nVision received 510k approval from the FDA for a novel device used for the early stage detection of ovarian cancer.
nVision completed a $4 million Series A financing led by Catalyst Heath Ventures in 2013 and a $12 million Series B financing led by Arboretum Ventures in 2016.
In April 2018, Boston Scientific (NYSE: BSX) announced the acquisition of nVision Medical for $275 million.
Founder and CEO: